Whole Genome Sequencing Identifies Crucial Diagnostic Biomarkers and Therapeutic Targets in Premature Coronary Artery Disease in South Asians: A Pilot Study

Iftikhar Ali Ch MD[1,2*], Azhar Chaudhry MBBS[3], Fazal Jalil Ph. D[4], Yasir Ali Ph. D[4], Waseem Iqbal[4], Yusra Javed MBBS[5], Salman Khalid MD[1], Azeen Razzaq MBBS[6], Muhammad Azhar MBBS[6], Amna Nadeem MBBS[1], Tayyab Afzal Ph. D[7], Naeem Tahirkheli MD[1], Ankur Kalra M.D, MSc. [9], Khurram Nasir MD[10].

Affiliation

[1] South Oklahoma Heart Research, Oklahoma City, OK, USA

[2] SSM Health Saint Anthony Hospital, Oklahoma City, OK, USA

[3] Armed Forces Institute of Cardiology, Rawalpindi, Pakistan

[4] Department Biotechnology, Abdul Wali Khan University Mardan, Pakistan.

[5] Chughtai Lab, Rawalpindi Pakistan

[6] Rawalpindi Medical University, Rawalpindi Pakistan

[7] Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

[8] Department of Cardiology, SUNY Upstate University, Syracuse, NY, USA

[9] Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA

*Corresponding Author:
Iftikhar Ali Ch MD, South Oklahoma Heart Research, Oklahoma City, OK, USA;
Email: babar_175@hotmail.com

Co- Corresponding Author: Yasir Ali, PhD, Department of Biotechnology, Abdul Wali Khan University Mardan, Pakistan; Email: Yasirali@awkum.edu.pk

Abstract

Whole genome sequencing (WGS) was conducted in a cohort comprising 12 individuals (5 cases vs 7 matched controls) to identify potential genetic variants associated with premature coronary artery disease (PCAD). High-integrity genomic DNA was sequenced with a minimum read depth of 10x, with a quality score threshold of Q30. Variant calling and stringent quality control identified over 8.8 million single-nucleotide polymorphisms (SNPs) per individual, with aggregate variant counts demonstrating comparable distributions across cases and control groups. Initial analysis identified 120 SNPs exclusively present in PCAD patients. Annotation of allele frequencies against the gnomAD database revealed that all protein-coding variants were rare (AF < 0.0001), and none were previously classified as pathogenic in the ClinVar database. Following annotation and filtration for protein-coding regions, 87 candidate genes were prioritized for further analysis (full list presented in supplementary data).

Subsequent comparative analyses identified SNPs that were either uniquely present or significantly enriched in the PCAD cohort compared to controls. Several notable SNPs were localized to genes implicated in diverse pathophysiological pathways associated with atherosclerosis, including lipid metabolism (*ELOVL2, ELOVL2-AS1 SUGP1, SULF2*), endothelial dysfunction (*DAB1, EFNA5MAP2K4*), inflammatory signaling (*BABAM2, CNTN5, DLEU7 TRAPPC9*), immune regulation (*DLEU7, IL4I1, KIR2DS4*), thrombosis (*MAP2K4, SULF2*), vascular remodeling (*ADAMTSL1, DOCK2, TBX5*) and metabolic processes (*GLIS3*). Additional variants were identified in genes associated with other biological mechanisms, including smooth muscle proliferation, oxidative stress, and other pathways *(NDOR1, PIPOX, SATB2,* and *TYW1)*. Collectively, this WGS pilot dataset delineates a comprehensive genomic landscape for elucidating molecular drivers of early-onset cardiovascular disease and constitutes a valuable resource for further functional validation and population-based genetic studies.

1. Introduction

Coronary artery disease (CAD) remains the leading cause of mortality worldwide, with South Asia experiencing a disproportionately high and escalating burden. According to the Global Burden of Disease (GBD) study, ischemic heart disease accounted for approximately 8.92 million deaths in 2015, underscoring its global health impact [1]. Of particular concern is the increasing incidence of premature CAD (PCAD), clinically defined as major cardiac events occurring before the age of 45 in men and 55 in women, with a more severe form affecting individuals under 40 years [2]. Epidemiological data of myocardial infarction (MI) cases reported that 21% of affected individuals were under 40, of which 79.8% were male, emphasizing a significant sex disparity and disproportionate impact on young men [3]. Notably, the incidence of acute MI demonstrates a marked age-dependent increase, from 2.1 per 100,000 person-years in individuals aged 20–29 to 16.9 in those aged 30–39 [4]. In Pakistan, the burden of cardiovascular disease (CVD) is escalating rapidly. As the world's fifth most populous country, Pakistan has witnessed decades of industrial and economic impoverishment alongside significant challenges, including regional conflicts, natural disasters, and underinvestment in healthcare. Consequently, while infectious diseases remain prevalent, the healthcare system is now facing a growing crisis of non-communicable diseases, particularly CVD. According to the 2019 GBD study, Pakistan's age-standardized incidence of CVD was 918.18 per 100,000 people (compared with the global rate of 684.33), and age-standardized death rate was 357.88 per 100,000 (compared to 239.85 globally) [5]. Additionally, data from the National Socioeconomic Registry Survey, comprising 34 million households, showed that 18.9% of participants self-reported having CVD [4] [5].

Globally, individuals of Indo-Asian origin exhibit the highest risk of developing CAD [6], hence establishing it as the leading cause of death in the Indo-Pakistani subcontinent. A national registry (2016–2019) analyzing percutaneous coronary intervention (PCI) data from 15,106 patients revealed that 52.6% had premature CAD (men aged 40–54; women aged 40–64), while 7.4% had extremely premature CAD (under 40 years) [7]. These statistics highlight a significant disease prevalence in younger populations, necessitating early interventions and preventive strategies.

The risk factors associated with PCAD differ across various ethnicities. Among Black populations, dyslipidemia, diabetes, and smoking are significant contributors, whereas in Whites, smoking is the primary factor. Among Hispanic populations, dyslipidemia, male sex, and family history are most prominent. Interestingly, no independent predictor has been found for Asian Indians [5]. The prevalence of PCAD is highest among American Indians and White populations (50%), followed by African Americans (30%) and Hispanics (20%). Among South Asians, family history is a key contributor, warranting deeper investigation into genetic predisposition, including gene variants related to lipid metabolism, vascular function, and coagulation pathways [8] [9]. The elevated prevalence of consanguinity within the South Asian population likely increases the risk of homozygous mutations, contributing to early-onset and more aggressive disease. This is supported by epidemiological data reporting a positive family history in 18% of PCAD and 23% of early PCAD cases, suggesting a substantial genetic or familial environmental clustering [7]. In Pakistan, high age-adjusted prevalence of diabetes (30.8%), hypertension (37% in adults), and tobacco use (~25% in adult males), coupled with a high consanguinity rate (58% first- or second-cousin marriages), synergistically amplify genetic risk [5].

Multiple studies have explored genetic contributors to CVD in South Asians, including PROMIS (Pakistan), BRAVE (Bangladesh), LOLIPOP (UK), and the START cohort (Canada) [10] [11] [12] [13]. These studies, along with the 1000 Genomes Project [14], have provided critical insight into gene-environment and gene-gene interactions. The C4D Genetics Consortium meta-analysis of four GWAS (PROMIS, LOLIPOP, PROCARDIS, and HPS) identified 59 single nucleotide polymorphisms (SNPs) linked to CAD, five achieved genome-wide significance, implicating genes involved in lipid metabolism, inflammation, and vascular remodeling [15]. Furthermore, a multiethnic GWAS meta-analysis combining seven non-South Asian and two South Asian cohorts identified 25 CAD-associated SNPs within or proximal to genes such as PECAM1 (inflammation), LMOD1 (vascular smooth muscle), and PROCR (coagulation) [16]. PROMIS study also identified six novel SNPs in the CX3CR1 gene specific to South Asians that were not reported in larger European studies, suggesting ethnicity-specific genetic architecture [17]. Another study in young South African Indians reported an association between the p53 Arg72 allele and PCAD, proposing it as a potential genetic marker for early disease [18]. Epigenetic research further supports the gene-environment interplay whereby environmental

exposures (e.g., diet, maternal health) modulate disease risk through gene regulation, as evident by the emergence of miR-21 as a potential epigenetic marker for atherogenic dyslipidemia in South Asians [19].

Despite these advancements, the role of genetics in PCAD and certain understudied populations, such as the Indo-Pakistan region, remains inadequately characterized, warranting the use of high-throughput whole genome sequencing (WGS) to identify PCAD-specific variants. Our study aims to address this critical gap by identifying novel mutations, SNPs, and structural variants in early-onset PCAD (onset before age 45) using WGS. Since many common diseases have a genetic component, stratification of individuals based on inherited DNA variation offers a promising avenue. While clinical applications have predominantly focused on identifying carriers of rare monogenic mutations, which are associated with several-fold increased risk, the majority of disease susceptibility is polygenic [20], and until recently, it has not been feasible to utilize polygenic predictors to identify individuals at a risk level comparable with that of monogenic mutations. Kher et al developed and validated genome-wide polygenic scores for five common diseases, determining that 8% of the population carries a greater than threefold increased risk for CAD [21]. This prevalence is 20 times higher than the carrier frequency of rare monogenic mutations that confer a similar risk. These findings suggest that the integration of polygenic risk prediction in clinical care should be considered, alongside discussion on relevant ethical challenges. Therefore, the current pilot phase analysis aims to investigate disease related genes and causative variants using WGS thereby identifying diagnostics markers and potential therapeutic targets for PCAD.

2.0 Methodology

2.1 Study Population

This retrospective case-control study enrolled 12 study participants, including 5 PCAD patients (PCAD group) and 7 matching controls (control group). Blood samples of the study participants were collected from Armed Forces Institute of Cardiology/ National Institute of Heart diseases, Rawalpindi, Pakistan. Inclusion criteria for patient selection were as follows: (1) clinical symptoms indicative of myocardial infarction (MI) lasting over 20 minutes within the previous

24 hours of index hospitalization, (2) ECG changes consistent with MI, such as new pathologic Q waves, at least 1 mm ST elevation in two or more contiguous limb leads, a new left bundle branch block, or persistent ST-T wave changes diagnostic of non-Q wave MI, and (3) those with elevated troponin-T levels.

Exclusion criteria included patients diagnosed with recent or active infection within the past 2 weeks, chronic infections (e.g., HIV, hepatitis B, hepatitis C, tuberculosis), chronic autoimmune diseases (e.g., rheumatoid arthritis, lupus), acute pericarditis, end-stage renal failure, history of malignancy, and those who refuse to provide consent. Individuals in the control groups were matched to cases by age, gender and co-morbidities (within 5-year age bands) without a history of cardiovascular disease.

2.2 Sample Collection
A blood sample (5ml) was collected from each study participant under the supervision of a certified cardiologist or physician. During sample collection, baseline characteristics and clinical information were documented using a specifically designed questionnaire. Following collection, blood samples were immediately transported under controlled conditions to the Chugtai laboratory Jail Road Lahore, Pakistan and stored at 4ºC until further processing.

2.3 DNA Extraction and Analysis
Genomic DNA was isolated from whole blood samples using the standard organic phenol-chloroform method, following the manufacturer's instructions (Sambrook, 1989). The purified DNA was quantified and stored at 4°C for subsequent experimentation.

2.4 Sample Quality Control
DNA integrity was assessed by electrophoresis on a 1% agarose gel. Quantification analysis was performed using a NanoPhotometer spectrophotometer (Implen GmbH), and DNA concentration and purity were subsequently determined with a Qubit 2.0 Fluorometer (Thermo Fisher Scientific).

2.5 Library Preparation

Genomic DNA was sheared to ~350 bp fragments using an ultrasonic processor. The resulting fragments were then used to construct sequencing libraries through a standardized workflow. The process including end repair, adenylation at the 3′ ends, adapter ligation, purification, and polymerase chain reaction (PCR) amplification. The resulting sequencing libraries were quantified using a Qubit 2.0 Fluorometer and samples were normalized to a working concentration of 1 ng/µl. Library fragment size distribution was validated using an Agilent 2100 Bioanalyzer system. Final library concentrations were confirmed by quantitative PCR prior to sequencing.

2.6 Whole Genome Sequencing:

Whole-Genome Sequencing (WGS) was performed using an Illumina NovaSeq 6000 (PE150) platform with the largest capacity S4 flow cell. FASTQ formatted files were received from the sequencing provider. Sequencing quality were checked using FastQC, which includes (1) more than 50Gbp bases in each FASTQ file (each sample have two paired FASTQ files), (2) 150bp length for all sequences, and (3) pass all the quality check terms in FastQC report, which include per base sequence quality, per sequence quality scores, per base sequence content, per sequence GC content, per base N content, sequence length distribution, sequence duplication levels, overrepresented sequences, adapter content. After checking the sequencing quality. Genome Reference Consortium Human Build 38 (GRCh38) reference panel provided by Genomic Analysis ToolKit (GATK) in GATK resource bundle was chose as reference genome. Sequencing alignment and variant calling were performed using the graphic process unit (GPU) accelerated GATK pipeline in Nvidia Clara Parabricks v4.3.1. After receiving GVCF files for each sample, joint calling was performed using GLnexus v1.2.6 to convert GVCF files into a joint-called VCF file.

2.7 Bayesian Model for Detecting Associations (BMDA) SNP Analysis Pipeline

This analysis pipeline started with the VCF file produced after WGS. The GFF (General Feature Format) or GTF (Gene Transfer Format) file were used for reference genome. BMDA analysis included the following steps:

1) Filtering samples based on quality score and depth of coverage:

The raw variant call format (VCF) file was filtered using "vcftools" using minimum quality score of 30, and minimum depth of coverage of 10 reads.

2) Basic stats of the raw VCF:

Program "vcf-stats" was used to extract the numbers of each SNP for each sample. Average ts/tv (transition SNPs to transversion SNPs) was 1.99.

3) Extracting the initial SNP report:

An in-house script was used to extract the initial report. The report was generated where only rows containing controls samples with identical genotypes and patients with different genotypes were picked.

4) Preparing the GFF and GTF file:

An annotation table was generated from the GTF annotation file to extract the relevant information.

5) Annotating the SNP report:

The initial SNP report from step 3 was amended with the gene annotation.

2.8 Variants annotation and filtering

Sequence alignment to the GRCh38 (hg38) reference genome was performed using the Burrows-Wheeler Aligner (BWA version 0.7.15), followed by duplicate removal with Picard. Subsequent processing, including indel realignment, base quality score recalibration, and variant calling, was conducted with the Genome Analysis Toolkit (GATK). ANNOVAR (v2019Oct24) was used for variant annotation. Allelic frequencies were filtered and verified using public genomic databases, including the Genome Aggregation Database (gnomAD), Kaviar Genomic Variant Database, the Greater Middle East (GME) Variome Project, and the 1000 Genomes Project (1000G).

Figure 1. Distribution of Single Nucleotide Polymorphism (SNP) Substitution Types Across 12 Samples. The stacked bar chart shows the counts of different SNP substitution types (e.g., A>G, C>T, T>C, etc.) across twelve whole genome sequencing samples (P1–P12). Each colored segment represents a specific nucleotide substitution, with transitions (e.g., A>G, C>T) and transversions (e.g., A>T, C>G) clearly visualized. The total SNP burden is comparable across samples, indicating consistent sequencing depth and variant calling quality. The most common substitutions include C>T and G>A, which are known transition mutations typically resulting from deamination events.

Figure 2. Comparison of Overall and Unique SNP Counts Across Whole Genome Sequencing Samples.
The bar and dot plot illustrate the total number of single nucleotide polymorphisms (SNPs) (blue bars, left y-axis) and unique SNPs (orange dots, right y-axis) for each individual sample (P1P–P11P). While the total SNP counts are relatively consistent across all samples, unique SNP counts show some inter-sample variability, suggesting potential individual-specific or population-specific variations. This comparison highlights both the sequencing depth and the uniqueness of genetic variation within each genome in the context of premature coronary artery disease analysis.

3.0 Results

3.1 Patient characteristics

This study comprised a cohort of 12 participants (5 PCAD cases, 7 controls). Cases were modestly older than controls (mean age 39.0 ± 3.4 vs 34.4 ± 6.3 years). The cohort was predominantly male (cases= 4 of 5, controls= 6 of 7). Adiposity indices trended higher among cases (mean BMI: 28.9 ± 6.4 kg/m² vs 25.1 ± 4.7 kg/m², weight: 81.7 ± 8.0 kg vs 72.9 ± 14.5 kg). Hypertension and dyslipidemia were documented in one case whereas no participant, in either group, reported diabetes mellitus, smoking history, chronic kidney disease, prior MI/PCI/CABG, or family history of CAD. Only 2 of 5 cases were on statin therapy prior to MI. Baseline medications listed in Table1.

3.2 Laboratory values

Lipid profiles were broadly similar between groups, with substantial variability. Mean total cholesterol was 163.0 ± 73.8 mg/dL in cases vs 174.0 ± 30.9 mg/dL in controls; LDL-C 87.8 ± 71.6 vs 125.8 ± 22.8 mg/dL; HDL-C 38.5 ± 4.5 vs 35.6 ± 3.0 mg/dL; and triglycerides 186.2 ± 87.2 vs 178.2 ± 61.2 mg/dL. HbA1c averaged 5.8 ± 0.5% in cases and 5.4 ± 0.1% in controls. Serum creatinine was modestly higher among cases (1.1 ± 0.2 vs 0.8 ± 0.1 mg/dL). Data were presented as mean ± SD or count 'n' (%).

3.3 Genetic testing results

Whole-genome sequencing (WGS) was performed on a cohort of 12 individuals to investigate potential genetic variants associated with PCAD. The cohort comprised 7 control individuals (samples P1P to P7P) and 5 confirmed PCAD cases (samples P8P to P12P). High-quality DNA libraries were sequenced with a minimum read depth of 10x and a quality score threshold of 30. Following variant calling and quality control, over 8.8 million single-nucleotide polymorphisms (SNPs) were detected per sample, with total SNP counts comparable across all individuals. Unique SNPs, representing potentially disease-associated or population-specific variations, were quantified separately and exhibited slight variability within the PCAD group. We identified 120 SNPs exclusively present in patients. All protein-coding variants annotated against gnomAD were rare (allele frequency < 0.0001) and none were previously classified as pathogenic in

ClinVar. These variants were annotated and filtered for protein-coding regions, yielding 87 candidate genes (full list is presented in Supplementary Data S1).

Comparative analyses identified SNPs uniquely present or significantly enriched in PCAD cases, mapped to genes involved in atherosclerosis, lipid metabolism, inflammation, and endothelial dysfunction. Several notable SNPs were identified in genes implicated in diverse pathophysiological pathways associated with atherosclerosis, including lipid metabolism (*ELOVL2, SUGP1, SULF2 ZNF679*), endothelial dysfunction (*ARAP2, EFNA5 MAP2K4, NABP, , POR, RAP1GAP*), inflammatory signaling (*BABAM2, CD28, CNTN5, DLEU7, HDAC9, ITPR1, POR, PLCB1 , TSPAN33, TRAPPC9*), immune regulation (*DLEU7, IL4I1, KIR2DS4*), thrombosis (*MAP2K4, PLCB1, RAP1GAP, SULF2,TSPAN33,*), vascular remodeling (*ADAMTSL1, BCAS3, DOCK2, ITGA8, TBX5,*), and metabolic processes (*ARHGAP44,GLIS3*). Additional variants were observed in genes linked to smooth muscle proliferation, oxidative stress or other processes *(ACAN, CDK14, LRP2, NDOR1, PIPOX, RUBCN, SATB2, TUBB4B, TYW1)*.

The *LINC01744* gene exhibited the largest number of variants (n=19), followed by *ELOVL2* with (n=14). *DAB1* and *TRERNA1* each showed 10 variants, while *DLEU7*, *KNTC1*, and *TPT1-AS1* had 9 each. *MAP2K4* carried 8 variants, and *ELOVL2-AS1* and *KCNIP4* had 7 variants each.

Figure 3. This heatmap visualizes the genotypic variation across 40 selected SNPs (y-axis), each labeled with its corresponding gene, in 12 study participants (x-axis). Samples Ctrl-1 to Ctrl-7 represent healthy controls, while patient-8 to patient-12 represent individuals with premature coronary artery disease (PCAD). A genotype heatmap shows the differences between controls and patients across all disease-associated SNPs. **Blue (0)**: Homozygous reference (0|0) – observed in all controls. **Light to dark red (1 or 2)**: Variant genotypes – seen only in patients. **Consistent red bands** across patient columns highlight recurrent SNPs potentially contributing to **PCAD**.

Figure 4. Bar chart illustrating the ten genes with the greatest number of SNPs identified across the WGS dataset with LINC01744 exhibiting the highest SNP burden (19 variants), followed by ELOVL2 (14 SNPs), DAB1 and TRERNA1 (10 each), DLEU7, KNTC1, and TPT1-AS1 (9 each). Other notable genes include MAP2K4 (8), ELOVL2-AS1 (7), and KCNIP4 (7).

Figure 5. Bar graph showing SNPs count per chromosome from WGS data, with Chromosome 1 exhibiting the highest SNP burden of variants (47), followed by chromosome 9 (29), chromosome 6 (25), and chromosome 12 (22). Chromosomes 3, 16, and 19 had the fewest SNPs (1 each).

4.0 Discussion

Functional relevance of genes with SNPs

As aforementioned, from a cohort of 12 individuals (5 PCAD patients and 7 healthy controls), we identified 120 SNPs exclusively present in patients. Protein-coding variants ($n = 87$ unique genes) underwent allele frequency annotation using gnomAD, all were rare ($AF < 0.0001$), and none were previously classified as pathogenic in ClinVar.

Here, we have briefly highlighted the role of these unique SNPs and the associated pathways in the pathophysiology of atherosclerosis.

4.1 Lipid metabolism

Emerging genomic evidence reflects a lipid-centric architecture in premature atherosclerosis, where inherited variation alters PUFA remodeling, LDL handling, and remnant lipoprotein clearance, driving vascular inflammation and plaque biology. Investigating genetic variants governing these pathways would help in risk prediction, early detection and novel treatment strategies. Integrating genetic and endophenotypic data would reveal biomarkers for early detection and patient categorization. Functional assay development in cellular models would help prioritize candidates for therapeutic targeting. A combined approach may provide a framework for elucidating the interpopulation heterogeneity and its contribution to atherosclerotic cardiovascular disease. The present study identified specific variants in genes associated with lipid metabolism, which are summarized in (Table 1).

Table 1. Variants in lipid-metabolism-related genes.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**ELOVL2**	14	childhood obesity	PUFA metabolism and lipid homeostasis	[22] [23]
2	**ELOVL2-ASI**	7	---	lncRNA for ELOVl2	[24]
3	**SUGP1**	1	CAD, High plasma LDL levels	Cholesterol metabolism, coagulation	[25]
4	**SULF2**	1	Fatty Liver disease. T2DM	impairs TRL clearance and promotes dyslipidemia	[26]

4.2 **Endothelial cell function**

Endothelial cells (ECs) orchestrate vascular homeostasis by regulating nitric oxide (NO)-mediated vasodilation, antithrombotic surface properties, barrier integrity, and leukocyte trafficking. Exposure to pathological stimuli, such as disturbed blood flow, hyperglycemia, dyslipidemia, tobacco exposure, or oxidative stress, induces endothelial dysfunction leading to reduced eNOS activity and NO bioavailability, elevated reactive oxygen species (ROS) driving redox-sensitive pathways (NF-κB/JNK); induction of cell surface adhesion molecules (ICAM-1, VCAM-1, E-selectin), resulting in diminished barrier function leading to increased permeability to inflammatory mediators (monocytes, and apoB lipoproteins). Endothelial dysfunction promotes monocyte/macrophage adhesion and transmigration to the vascular intimal layer, leading to lipid retention, foam-cell formation, and VSMC phenotypic switching, resulting in plaque growth and instability. Against this pathophysiological framework, the variants below converge on endothelial signaling, redox balance, adhesion, and repair—offering biologically coherent routes from genotype to premature atherosclerosis. The current study identified suspected variants in 6 EC function-related genes (Table 2).

Table 2. Variants identified in EC-function-related genes

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**DAB1** (Disabled-1)	8		Activation of the Reelin pathway activates NF-κB, increases expression of ICAM-1, VCAM, and E-selectin	[27], [28] [29]
2	**ARAP2** (Arf/Rho GAP)	15		Integrin signaling, leukocyte–endothelial adhesion	[30], [31]
3	**MAP2K4**	7		Activator of JNK, promotes endothelial apoptosis and pro-inflammatory gene expression	[32]
4	**EFNA5** (Ephrin-A5)	2	Cardiovascular development, Atherosclerosis	Monocyte adhesion via EPHA2/EPHA4 and RhoA-cytoskeletal remodeling, Ca²☐/NFAT pathway	[33] [34]
5	**POR** (NADPH–cytochrome P450 oxidoreductase)	1		eNOS/AKT signaling, NO bioavailability, EC dysfunction.	[35] [36] [37]
6	**RAP1GAP** Rap1 GTPase-activating protein	1	myocardial infarction (MI)	Endothelial NO release, Worsen MI via the AMPK/SIRT1/NF-κB pathway	[38] [39]

4.3 Inflammatory pathways

Atherosclerosis is a chronic inflammatory disease characterized by endothelial dysfunction which leads to to subendothelial retention of lipoproteins, activation of adhesion molecules (VCAM-1, ICAM-1, E-selectin), and chemokines resulting in the recruitment of monocytes and T cells into the intima. This cascade of innate immune signaling (TLR–MyD88–NF-κB, NLRP3–IL-1β) amplifies macrophage activation, foam cell formation, and impairs efferocytosis. Concurrently, VSMC phenotypic switching and extracellular-matrix production drive plaque growth and vulnerability. As detailed in Table 3, the present analysis identified variants in 9 inflammatory pathway-related genes.

Table 3. Variants identified in inflammatory pathway-related genes.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**BABAM2** BRISC/BRCA1-A complex mem2	9	Acute myocardial infarction,	Intersects TNF/NF-κB and cell-death/DNA-damage axes	[40] [41] [42]
2	**DLEU7**	9	Cardiovascular Diseases	inhibits the B-cell receptors, dampening NF-κB/NFAT signaling	[43] [44]
3	**CNTN5**	8		neuronal adhesion protein	[45] [46] [47] [48]
4	**TRAPPC9**	4		Promotes NF-κB signaling	[49]
5	**HDAC9**	1	CAD Large artery ischemic stroke	Increasing pro-inflammatory signaling via IKK/NF-κB	[50] [51]
6	**CD28**	1	Acute coronary syndrome (ACS), Rheumatoid arthritis (RA)	Expression on Tregs supports immune regulation and appears protective	[52] [53]
7	**ITPR1** (IP□ receptor 1)	1	CAD	IP□R-mediated Ca²□ release, NO signaling, VSMCs contractility, phenotype switching	[54] [55] [56]
8	**TSPAN33**	1		macrophage activation via NOTCH / TLR	[57]
9	**PLCB1**	1	Coronary artery aneurysm (CAA) Kawasaki disease	Reduce endothelial cell inflammation, Platelet activation pathways downstream of GPCR.	[58] [59]

4.4 Immune-related pathways

Atherosclerosis is a maladaptive immune response to retained apoB-lipoproteins within the arterial wall. Innate sensors (TLRs, scavenger receptors) on endothelial cells (ECs), macrophages, and dendritic cells detect modified LDL and cellular debris, activating NF-κB and inflammasomes (e.g., NLRP3→IL-1β/IL-18). This inflammatory milieu is perpetuated through monocyte recruitment, macrophage polarization, defective efferocytosis, and neutrophil extracellular traps (NETs), creating a non-resolving inflammatory cascade. Adaptive immunity layers amplify this niche wherein Th1- and Th17-derived cytokines (IFN-γ, IL-17) exacerbate vascular inflammation while Tregs counteract this progression via IL-10/TGF-β. B-cells exhibit a dichotomous response, with natural IgM against oxLDL being protective, whereas some B2 responses promote disease. Natural killer (NK) cells and cytotoxic T cells can add plaque-destabilizing cytotoxicity. Genes that bias Treg/Th17 balance, NK activation thresholds, or cytokine set-points can therefore shift risk—offering handles for diagnostics (circulating proteins/cell-subset signatures) and therapeutics (pathway-targeted immunomodulation). The present whole genome sequencing analysis identified one variant each in KIR2DS4 and IL4I1 (Table 4).

Table 4. Variants identified in immune-related genes.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**KIR2DS4**	1	HIV	**Reduce CD4+ T-cell counts** in chronic HIV-1	[60]
2	**IL4I1** (interleukin-4–induced-1)	1		Promote regulatory T cells (Tregs). Suppress pro-inflammatory Th17 cells	[61]

4.5 **Thrombotic pathways**

Myocardial infarction (MI) represents the clinical manifestation of ruptured atherosclerotic plaque exposing tissue factor and subendothelial matrix, leading to a cascade of platelet activation and coagulation, which culminates in occlusive coronary thrombosis. Genetic predispositions and acquired risk factors that heighten platelet reactivity, enhance thrombin generation, or impair endothelial anticoagulation mechanisms alter this balance toward occlusive arterial thrombosis. These variants may contribute to early-onset MI through thrombogenic

pathway activation, even with minimal coronary atherosclerosis. The variants identified in thrombotic pathways are listed in Table 5.

Table 5. Variants associated with thrombotic pathways.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	PLCB1	1		Platelet Ca²☐ signaling granule release	[58]
2	TSPAN33	1	---	increases ADAM10 activity	----
3	MAP2K4	1		Lower the threshold for secretion, stabilize thrombi	
4	SULF2	1		Reducing local AT/TFPI efficacy	[62]

4.6 Vascular remodeling

Vascular remodeling is the structural and cellular reconfiguration of the arterial wall in response to hemodynamic load, injury, and inflammation. It encompasses endothelial activation, smooth-muscle cell (SMC) phenotypic switching (contractile to synthetic/migratory), extracellular-matrix (ECM) reorganization, microfibril/TGF-β signaling, integrin-mediated transduction, and (neo)angiogenesis within the intima and media. While adaptive remodeling preserves lumen caliber, maladaptive remodeling (excess SMC migration/proliferation, aberrant ECM deposition, fibrous cap thinning, and plaque neovascularization) promotes plaque growth, instability, and thrombosis. Genetic variants that alter leukocyte–endothelial crosstalk, SMC adhesion/motility, ECM architecture, or endothelial polarity/angiogenesis can predispose an individual to maladaptive remodeling, thereby increasing susceptibility toward premature atherogenesis and MI. This whole-genome sequencing identified variants in five vascular remodeling-associated genes (Table 6).

Table 6. Variants identified in vascular remodeling-associated genes.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	DOCK2	2	Myocarditis, cardiac graft rejection	Knockdown blunts TNF-α–induced ICAM-1/VCAM-1/MCP-1 and NF-κB activation.	[63] [64] [65]
2	ADAMTSL1	2		Binds fibrillin-1, modulates TGF-β bioavailability.	[66]
3	TBX2	3	Cardiovascular	Developmental transcription	[67] [68]

			malformations	factor, linked to cardiac electrical traits and AF.	[69] [70]
4	**ITGA8**	1		Regulates differentiation, migration, and ECM/fibrotic responses.	[71], [72]76
5	**BCAS3**	2	Coronary artery disease	Angiogenesis and vascular remodeling activate CDC42 and the actin cytoskeleton.	[73] [74]

4.7 **Metabolic pathways**

Metabolic syndrome, diabetes, and insulin resistance are potent atherogenic precursors because they create a lipoprotein-rich, pro-inflammatory, NO-deficient, and prothrombotic vascular environment, thereby transforming metabolic stress into endothelial dysfunction, plaque growth, and ultimately thrombotic coronary events. Genetic determinants of insulin resistance are of significant interest for advancing our understanding of mechanistic pathways leading to premature atherosclerosis. The present analysis identified five variants in two metabolic pathway-related genes (Table 7).

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**GLIS3** β-cell transcript factor	4	Insulinopenia, hyperglycemia,	adult β-cell function, insulin gene transcription	[75] [76]
2	**ARHGAP44**	1	Glucose metabolism and neuronal development	Associated with HbA□C levels	[77]

Table 7. Variants identified in metabolic pathway-related genes.

4.8 **Vascular Inflammation–Remodeling–Thrombosis (VIRT) Pathway in PCAD**

This whole-genome sequencing revealed the involvement of nine VIRT pathway-related genes harboring 32 variants (Table 8).

Table 8. Variants identified in VIRT pathway-related genes.

Sr. Number	Genes	Number of Variants	Disease	Pathways	Reference
1	**SATB2**	15		Endothelial senescence at 9p21/CDKN2A/B locus, VSMC osteogenic	[78] [79]

				programming via RUNX2	
2	**NDOR1** NADPH-dependent diflavin oxidoreductase 1	7	diabetic vascular aging	Affects redox-sensitive signaling pathways such as NF-κB and MAPKs	[80] [81] [82]
3	**TYW1**	2		Modifies tRNA^Phe (wybutosine pathway)	[83]
4	**RUBCN** (Rubicon)	2	acute coronary syndrome (ACS)	LC3-associated phagocytosis (LAP); impairs efferocytosis,	[84]
5	**PIPOX**	2		Glycine/sarcosine metabolism, generate H_2O_2	[85] [86]
6	**LRP2**	1		Renin-angiotensin homeostasis,	[87]
7	**CDK14**	1		Cell-cycle and Wnt signaling	[88]
8	**TUBB4B** β-tubulin isoform	1		GJA1–PI3K/AKT/KLF4 pathway	[89]
9	**ACAN** Aggrecan	1		Promote VSMC apoptosis Plaque instability	[90]

Conclusion

This WGS pilot dataset provides a comprehensive genomic landscape for evaluating molecular drivers of early-onset cardiovascular disease and constitutes a valuable resource for further functional and population-based studies. Our preliminary findings converge on a single disease framework for PCAD: an endothelial–immune–metabolic remodeling axis that amplifies lipid retention, vascular inflammation, smooth-muscle reprogramming, and thrombosis. Within this framework, several loci emerge as pathway anchors for premature atherosclerosis leading to MI at a young age, including lipid pathway (*ELOVL2, ELOVL2-AS1, SULF2),* and endothelial dysfunction (EC) pathway (*DAB1, MAP2K4, EFNA5),* inflammatory pathway (*BABAM2, TRAPPC9, CNTN5, DLEU7),* vascular remodeling pathway (*DOCK2, ADAMTSL1, TBX5/TBX2 locus),* metabolic pathway (*GLIS3),* and VIRT pathway (*TYW1, SATB2, NDOR1, PIPOX).* Collectively, these genes delineate coherent routes from genotype to disease phenotype, encompassing lipid handling, endothelial activation/adhesion, immune amplification, SMC/ECM remodeling, metabolic/redox stress, and thrombotic readiness. This data provides critical insights into the genetic architecture of the disease and identifies specific, testable targets for development of novel biomarkers and targeted therapeutic interventions in PCAD. These genomic findings are preliminary and hypothesis-generating, derived from a small WGS pilot (5 PCAD cases, 7 controls) intended to demonstrate feasibility and establish analytic workflows.

The candidate loci and pathways require replication in larger, adequately powered cohorts and independent datasets before any cellular or molecular follow-up, biomarker development, or clinical inference. A larger sample study is underway to provide the statistical power needed to validate these signals.

References

[1] A. P. L. Z. Z. M. P. M. A. A. A. E. W. M. Khoja A, "Risk factors for premature coronary artery disease (PCAD) in adults," 2021.

[2] A. S. D. M. Bansal SK, "Advanced Atherogenic Index for the Assessment of Consolidated Lipid Risk in Premature," 2016.

[3] B. D. S. A. D. S. D. E. Yang J, "Risk Factors and Outcomes of Very Young Adults Who Experience Myocardial," 2020.

[4] P. A. L. J. H. S. Jortveit J, "Incidence, risk factors and outcome of young patients with myocardial infarction," 2020.

[5] H. B. Samad Z, "Cardiovascular Diseases in Pakistan: Imagining a Postpandemic, Postconflict Future," 2023.

[6] Q. Z. C. N. Jafar TH, "Coronary artery disease epidemic in Pakistan: more electrocardiographic evidence of ischaemia," 2008.

[7] M. R. B. F. K. M. K. S. Ullah W, "Comparison of Premature, Extremely Premature, and Older Adults With Coronary Artery," 2023.

[8] N. S. E. A. A. S. Amin AP, "The effect of ethnicity on the relationship between premature coronary artery disease," 2009.

[9] G. N. Sharma M, "Premature coronary artery diseasein Indians and its associated risk factors," 2005.

[10] A. D. F. I. Chowdhury R, "The Bangladesh Risk of Acute Vascular Events (BRAVE) Study: objectives and," 2015.

[11] S. W. P. V. S. J. Tan T-S, "Coronary heart disease in Indian," 2014.

[12] H. P. Z. W. R. A. Saleheen D, "Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease," 2017.

[13] V. A. G. M. M. K. Anand SS, "Rationale and design of South Asian birth cohort (START): a Canada-India collaborative," 2013.

[14] "1000 Genomes | A Deep Catalog of Human Genetic Variation.," 2017.

[15] H. J. S. D. C. J. Peden JF, "A genome-wide association study in Europeans and South Asians identifies 5 new," 2011.

[16] Z. W. B. D. H. W. JMM H, "Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms," 2017.

[17] S. N. Z. W. X. C. F. M. Golbus JR, "Common and rare genetic variation in CCR2, CCR5, or CX3CR1and risk of atherosclerotic," 2016.

[18] P. A. R. P. M. D. Khan S, "The Arg72 variant of the p53 functional polymorphism (rs1042522) is associated with coronary," 2016.

[19] S. K. M. C. M. A. Flowers E, "MicroRNA associated with atherogenic dyslipidemia in South Asian men.," 2013.

[20] F. J. T. T. M. A. Fuchsberger C, "The genetic architecture of type 2 diabetes," 2016.

[21] C. M. A. K. H. M. R. C. Khera AV, "Genome-wide polygenic scores for common diseases identify individuals with risk," 2018.

[22] Z. C. G. A. M. D. G. E. Maguolo A, "Influence of genetic variants in FADS2 and ELOVL2," 2021.

[23] M. K. J. H. C. C. D. L. E. B. L. S Aslibekyan, "Genetic variation in fatty acid elongases is not associated," 2012.

[24] Z. C. G. A. M. D. G. E. Maguolo A, "Influence of genetic variants in FADS2 and ELOVL2," 2021.

[25] Y. C. T. E. N. D. Kim MJ, "SUGP1 is a novel regulator of cholesterol metabolism," 2016.

[26] B. B. A. F. Kim TH, "Knockout of sulfatase 2 is associated with decreased steatohepatitis," 2020.

[27] M. G. M.-N. G.-O. Eva Jover, "Expression of the lymphangiogenic reelin is associated," 2025.

[28] H. L. X. X. Y. I. Ding Y, "Loss of Reelin protects against atherosclerosis by reducing," 2016.

[29] W. D. C. Y. C. C. Li Y, "Genome-Wide Association and Functional Studies Identify SCML4," 2018.

[30] J. X. Y. H. R. P. Chen PW, "ARAP2 signals through Arf6 and Rac1 to control focal adhesion morphology," 2013.

[31] G. J. P. T. C. Nikki R. Paul, "Endocytic Trafficking of Integrins in Cell Migration," 2015.

[32] C. A., "Mitogen-Activated Protein Kinase Kinase 4 (MKK4," 2000.

[33] Y. A. J. A. P. Funk SD, "EphA2 activation promotes the endothelial cell inflammatory response," 2012.

[34] S.-a. S. J. S. H. M. J. L. Yuan Zhu, "Recent advances of the Ephrin and Eph family," 2024.

[35] P. S. K. N. Udhane SS, "Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L," 2017.

[36] F. I., "Cytochrome P450 and Vascular Homeostasis," 2001.

[37] R. C. G.-D. A. M. N. Malacarne PF, "Loss of Endothelial Cytochrome P450 Reductase Induces Vascular Dysfunction in Mice.," 2022.

[38] C.-W. M., "Rap1 in endothelial biology," 2017.

[39] L. X. X. W. W. S. Shan T, "Rap1GAP exacerbates myocardial infarction by regulating the AMPK/SIRT1/NF-κB," 2024.

[40] A. Matsumori, "Nuclear Factor-κB is a Prime Candidate for the Diagnosis," 2023.

[41] Z. H. C. J. L. W. H. J. Gao Z, "Clinical value of BRE-AS1 in myocardial infarction and its role in myocardial infarction-induced," 2024.

[42] H. G. P. J. K. N. Kovács ZJ, "DNA-dependent phase separation by human SSB2 (NABP1/OBFC2A) protein points to adaptations," 2024.

[43] B. G. L. P. G. S. Kichaev G, "Leveraging Polygenic Functional Enrichment to Improve GWAS Power," 2019.

[44] S. N. J. H. Jackson SW, "Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell," 2016.

[45] "The Human Protein Atlas".

[46] D. A. Arango Duque G, "Macrophage Cytokines: Involvement in Immunity," 2014.

[47] L. A. A. Ngo, "Plasma protein expression profiles, cardiovascular disease, and," 2021.

[48] K. G. F. N. A. M. S. I. Smirnov A, "Unexpected phenotypic effects of a transgene integration," 2018.

[49] H. N. N. A. Mbimba T, "Novel insights into its trafficking and signaling pathways in health and disease," 2018.

[50] B. S. G. A. S. C. Bellenguez C, "Genome-wide association study identifies a variant in HDAC9," 2012.

[51] C.-J. T. B. Y. Asare Y, "Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic," 2020.

[52] D. S. K. J. D. I. Bullenkamp J, "Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. Eur Heart J Cardiovasc Pharmacother," 2016.

[53] M. G. S. M. A. G. M. E. B. B. Roberto Gerli, "CD4+CD28− T Lymphocytes Contribute to Early Atherosclerotic," 2004.

[54] Z. L. J. R. T. C. Lin Q, "Inositol 1,4,5-Trisphosphate Receptors in Endothelial Cells," 2019.

[55] T.-S. H. S. L. H.-C. H. Z. C. Ming He, "Atheroprotective Flow Upregulates ITPR3 (Inositol 1,4,5-Trisphosphate Receptor 3)," 2019.

[56] Z. F. H. L. Z. X. Huang F, "Inositol 1,4,5-trisphosphate receptors regulate vascular smooth muscle cell proliferation," 2024.

[57] L.-L. S. G.-R. J. Ruiz-García A, "The Tetraspanin TSPAN33 Controls TLR-Triggered," 2016.

[58] C. J. L. X. T. H. C. W. Lin YJ, "Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in," 2015.

[59] O. S., "Activation of platelet function through G protein-coupled receptors," 2006.

[60] D. A. W. C. G. P. Merino AM, "KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and," 2014.

[61] D. Y. D. Q. Shen R, "IL-4-Induced Gene 1: A Potential Player in Myocardial Infarction," 2024.

[62] B. B. A. F. C. N. Kim TH, "Knockout of sulfatase 2 is associated with decreased steatohepatitis," 2020.

[63] X. S. L. H. Z. F. Ji L, "Insights from DOCK2 in cell function and pathophysiology," 2022.

[64] F. L. Z. X. Xia Guo, "Abstract 537: Dock2 Deficiency Mitigates High-Fat Diet," 2017.

[65] A. O. C. D. T. T. Qian G, "DOCK2 Promotes Atherosclerosis by Mediating the Endothelial Cell Inflammatory Response," 2024.

[66] A. S. Hubmacher D, "ADAMTS proteins as modulators of microfibril formation," 2015.

[67] B. B. Mori AD, "TBX5 mutations and congenital heart disease," 2004.

[68] B. J. J. Y. S. B. van Setten J, "PR interval genome-wide association meta-analysis identifies 50 loci," 2018.

[69] B. G. K. B. Diman NYSG, "Tbx5 Is Required for Avian and Mammalian Epicardial," 2014.

[70] Z. S. X. Y. L. S. Zang X, "SNP rs3825214 in TBX5 is associated," 2013.

[71] J. A. D. C. F. F. Z. C. Volkert G, "Contribution of the α8 Integrin Chain to the Expression of Extracellular Matrix Components," 2014.

[72] M. D. S. D. H. X. Chen R, "Phenotypic Switching of Vascular Smooth Muscle Cells in Atherosclerosis," 2023.

[73] D. C. D. P. Quaye LNK, "The Genetics of Coronary Artery Disease," 2023.

[74] S. M. S. W. Hartmann K, "Interpreting coronary artery disease GWAS results: A functional genomics approach assessing biological," 2022.

[75] C. B. C. L. Yang Y, "Sustained expression of the transcription factor GLIS3," 2013.

[76] P. F. V. O. C. M. Nogueira TC, "GLIS3, a Susceptibility Gene for Type 1 and Type 2 Diabetes," 2013.

[77] L. P. T. B. L. J. Wang S, "Novel Gene ARHGAP44 for Longitudinal Changes," 2024.

[78] W. Y. J. D. S. W. Z. M. Wu T, "SATB2, coordinated with CUX1, regulates IL-1β-induced," 2023.

[79] W. J. G. X. B. Y. Mao YY, "Circ-SATB2 upregulates STIM1 expression and regulates vascular smooth muscle cell proliferation," 2018.

[80] B. PC., "Cytoplasmic and Mitochondrial NADPH-," 2019.

[81] W. X. C. J. W. M. Z. C. Wang S, "Identification of key genes and biological pathways associated with vascular aging in," 2024.

[82] B. I. C. V. Banci L, "Molecular view of an electron transfer process essential for iron–sulfur protein biogenesis," 2013.

[83] W. K. Z. C. L. N. Zhao Y, "The function of tRNA-derived small RNAs in cardiovascular diseases," 2024.

[84] R. J. M. W. Grazide MH, "Plasma levels of autophagy regulator Rubicon are inversely associated with acute coronary syndrome," 2024.

[85] M. E. K. O. Natarajan SK, "Evidence for Pipecolate Oxidase in Mediating Protection Against Hydrogen Peroxide Stress.," 2016.

[86] J. E. G. T. Dziedzic M, "Interplay Between Plasma Glycine and Branched-Chain Amino Acids Contributes to the Development," 2024.

[87] W. Y. W. C. H. D. W. C. B. A. Ye F, "Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report," 2019.

[88] A. V, "Control of vascular cell proliferation and migration," 2004.

[89] Z. J. W. X. Q. Z. Z. Z. W. Y. He S, "Organoid Modeling and Single-Cell Profiling Uncover the Migration Mechanism of Smooth Muscle," 2024.

[90] L. C. A. S. Koch CD, "Aggrecan in Cardiovascular Development," 2020.

[91] 4.-T. Atheroprotective Flow Upregulates ITPR3 (Inositol 1, "Ming He, Tse-Shun Huang, Shuai Li, Hsiao-Chin Hong,," 2019.

[92] "Recent advances of the Ephrin and Eph family in cardiovascular," 2024.

Modified: 11.8.2025.IAC

To,
Principal Investigator: **Col. Azhar Ali Chaudhry**
Institute: **AFIC/NIHD, Rawalpindi**

Subj: **IERB approval letter for the study on topic:**

"Investigation of Clinical Determinants and Genetic Variants Associated with Premature Coronary Artery Disease (PCAD) - A Pilot Study"

Dear Researcher!
　　With reference to subject research proposal presented on, **12th Dec, 2024** Synopsis Reg#: **S/189/2024** has been reviewed and approved by the IERB, AFIC/NIHD subj to following conditions:

- Approval is valid only for the topic, data collection procedure and intervention (if any) presented in the research proposal duly approved by IERB committee AFIC/NIHD.
- The researcher is bound to notify and seek fresh approval from this Review Board in case of any amendments in the research protocol or terms of the approved application concerning to:
  - Health and safety of the participants in compliance with the conditions and principles of Good Clinical Practice
  - Applicable PMRC guidelines and regulations
  - Data collection process can only commence after seeking IERB approval.
- IERB approval is valid for 2 years from the date of signing of this letter.
  Kind Regards,

Professor Brigadier
Dr. Muhammad Nadir Khan Brig Khan
(Muhammad Nadir Khan)
MBBS, FCPS (Medicine) (USA)
FCPS (Cardiology),
Fellowship Intervensional Cardiology (UK)
Professor of Cardiology
AFIC & NIHD Rawalpindi, Pakistan

Brig
Dy Comdt / Dy Dir-I (P&A)
Chairperson IERB
(Khurram Akhtar)

Dated: 29 Apr, 2025

Brig
Khurram Akhtar
Dy Comdt/Dy Dir-I (P&A)
AFIC & NIHD Rwp

National Institutes of Health
Health Research Institute
National Bioethics Committee for Research (NBC-R)
✱✱✱✱✱✱✱

Ref: No.4-87/NBCR-1310/25-26/980   **Date: December 8, 2025**

Dr. Fazal Jalil
Abdul Wali Khan University Mardan,
Mardan, Pakistan.

Subject: **Investigating Genetic Variants and Genes Associated with Premature Coronary Artery Disease: A step towards early diagnosis and tailored interventions (NBCR-1310).**

Dear Dr. Fazal Jalil

      I am pleased to inform you that the above mentioned project has been approved by the "Research Ethics Committee" of NBC-R **for a period of one year.**

Principle Investigator	Dr. Fazal Jalil Abdul Wali Khan University Mardan, **Mardan, Pakistan.**
Protocol Version	N/A
Collaboration Institutions.	1. Armed Forces Institute of Cardiology, Saddar Rawalpindi, Pakistan 2. Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan 3. University of Hong Kong

      For the continuation of project in the next years, you have to submit a progress report. Kindly keeps the NBC-R updated about the progress of the project and submit the formal final report upon completion.

Yours sincerely,

(Prof. Dr. Saima Perwaiz Iqbal)
Chairperson
National Bioethics Committee for Research